The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine

Journal of Cellular Biochemistry

Volumn 105, Issue 1, 2008, Pages 245-254

  Liu, Angen ^a,b   Yoshioka, Ken Ichi ^a,c   Salerno, Vincenzo ^a   Hsieh, Peggy ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

5 fluouracil; ATR; Colorectal cancer; DNA damage; Mismatch repair

Indexed keywords

ATR PROTEIN; DNA; DOXYCYCLINE; FLOXURIDINE; FLUOROURACIL;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPLICATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MISMATCH REPAIR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA MISMATCH REPAIR; ENZYME ACTIVATION; FLOXURIDINE; HUMANS; HYDROXYLAMINES; MUTS DNA MISMATCH-BINDING PROTEIN; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 51849109383     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21824     Document Type: Article

References (39)

1. An Q, Robins P, Lindahl T, Barnes DE. 2007. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 67:940-945.
2. Andersen S, Heine T, Sneve R, Konig I, Krokan HE, Epe B, Nilsen H. 2005. Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts. Carcinogenesis 26:547-555.
3. Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y, Golemis EA, Genuardi M, Neri G. 1999. MED1, a novel human methyl-CpG-binding endo nuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci USA 96:3969-3974.
4. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G. 2005. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11:8332-8340.
5. Berry SE, Davis TW, Schupp JE, Hwang HS, de Wind N, Kinsella TJ. 2000. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 60:5773-5780.
6. Berry SE, Loh T, Yan T, Kinsella TJ. 2003. Role of MutSalpha in the recognition of iododeoxyuridine in DNA. Cancer Res 63:5490-5495.
7. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalicr RS, Howell SB, Boland CR. 1999. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131.
8. Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A. 2003. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 100:15071-15076.
9. Duckett DR, Bronstein SM, Taya Y, Modrich P. 1999. hMutSa- and hMutLa-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci USA 96:12384-12388.
10. Fischer F, Bacrenfaller K, Jiricny J. 2007. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 133:1858-1868.
11. Fortini P, Bignami M, Dogliotti E. 1990. Evidence for AP site formation related to DNA-oxygen alkylation in CHO cells treated with ethylating agents. Mutat Res 236:129-137.
12. Guo Z, Kumagai A, Wang SX, Dunphy WG. 2000. Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Genes Dev 14:2745-2756.
13. Hardeland U, Bentele M, Jiricny J, Schar P. 2003. The versatile thymine DNA-glycosylase: A comparative characterization of the human, Drosophila and fission yeast orthologs. Nucleic Acids Res 31:2261-2271.
14. Hekmat-Nejad M, You Z, Yee MC, Newport JW, Cimprich KA. 2000. Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint. Curr Biol 10:1565-1573.
15. Iyer RR, Pluciennik A, Burdett V, Modrich PL. 2006. DNA mismatch repair: Functions and mechanisms. Chem Rev 106:302-323.
16. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morulas JD, Nicolas-Perez D, Paya A, Alenda C. 2006. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848-855.
17. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. 1994. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N- nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54:4308-4312.
18. Kunkel TA, Erie DA. 2005. DNA mismatch repair. Annu Rev Biochem 74:681-710.
19. Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Buttner R, Sauerbruch T. 2007. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis 22:145-152.
20. Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, Avdievich E, Jin B, Werling U, Parris T, Kurihara N, Umar A, Kucherlapati R, Lipkin M, Kunkel TA, Edelmann W. 2004. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 64:517-522.
21. Liu A, Takakuwa T, Fujita S, Ham MF, Luo WJ, Daibata M, Aozasa K. 2005. Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma. Lab Invest 85:436-446.
22. Liuzzi M, Talpaeri-Borle M. 1985. A new approach to the study of the base-excision repair pathway using methoxyamine. J Biol Chem 260:5252-5258.
23. Longley DB, Harkin DP, Johnston PG. 2003. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
24. Meyers M, Hwang A, Wagner MW, Boothman DA. 2004. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44:249-264.
25. Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA. 2003. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22:7376-7388.
26. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. 2005. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280:5516-5526.
27. Mojas N, Lopes M, Jiricny J. 2007. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev 21:3342-3355.
28. Nghiem P, Park PK, Kim Y-S, Dcsai BN, Schreiber SL. 2002. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 277:4428-4434.
29. Popat S, Hubner R, Houlston RS. 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618.
30. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. 2003. Tumor microsatellite-insrability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257.
31. Schofield MJ, Hsieh P. 2003. DNA mismatch repair: Molecular mechanisms and biological function. Ann Rev Microbiol 57:579-608.
32. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, Jiricny J. 2004. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 18:1331-1344.
33. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. 2004. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: Implications for chemosensitivity and resistance. Gastroenterology 127:1678-1684.
34. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling DA, Kinsella TJ. 2003. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 63:838-846.
35. Turner DP, Cortellino S, Schupp JE, Caretti E, Loh T, Kinsella TJ, Bellacosa A. 2006. The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66:7686-7693.
36. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA. 1997. Correction of hypermutability, N-methyl-N′-nilro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57:3949-3955.
37. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, Kucherlapati R, Kolodner RD, Edelmann W. 2004. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 6:139-150.
38. York SJ, Modrich P. 2006. Mismatch repair-dependent iterative excision at irreparable O6-methylguanine lesions in human nuclear extracts. J Biol Chem 281:22674-22683.
39. Yoshioka K, Yoshioka Y, Hsieh P. 2006. ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22:501-510.